{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:33:19Z","timestamp":1789583599498,"version":"build-2803163510"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      <jats:italic>ESR1<\/jats:italic>\n                      alterations present a common mechanism of resistance to endocrine therapy (ET) in hormonally driven tumors. The clinical significance of these alterations continues to evolve with newly approved targeted therapies and a range of ongoing investigational trials.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective study of 2574 breast cancer (BC) and 1110 gynecologic cancer samples that underwent whole exome and whole transcriptome profiling was conducted to assess the distribution of\n                      <jats:italic>ESR1<\/jats:italic>\n                      and associated co-alterations in local (primary breast or regional lymph node) versus metastatic BC samples and in the major BC subtypes. Prior treatment history was unknown.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:italic>ESR1<\/jats:italic>\n                      alterations were present in 6.2% (n\u2009=\u2009159\/2574) of BC samples and 3.4% (n\u2009=\u200938\/1110) of gynecologic cancer samples. In HR\u2009+\u2009\/HER2- BC,\n                      <jats:italic>ESR1<\/jats:italic>\n                      alterations overall and\n                      <jats:italic>ESR1<\/jats:italic>\n                      missense mutations were more frequent in samples from metastatic compared to local\/regional sites (overall: n\u2009=\u200986\/321 (26.8%) and n\u2009=\u200953\/1427 (3.7%), respectively (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt; 0.001); missense: n\u2009=\u200972\/321 (22.4%) and n\u2009=\u200920\/1427 (1.4%), respectively (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001)). Whole transcriptome sequencing detected\n                      <jats:italic>ESR1<\/jats:italic>\n                      fusion genes in 2.1% (n\u2009=\u200955\/2574) of BC samples and in 1.9% (n\u2009=\u200921\/1110) of gynecologic cancer samples, and\n                      <jats:italic>CCDC170<\/jats:italic>\n                      was the most common fusion partner in both cancer types. In HR\u2009+\u2009\/HER2- BC,\n                      <jats:italic>ESR1<\/jats:italic>\n                      fusions were more common in metastatic samples compared to local\/regional (n\u2009=\u200917\/321 (5.3%) and n\u2009=\u200929\/1427 (2.0%), respectively;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). Evaluation of 21 therapeutically actionable biomarkers identified co-alterations enriched in\n                      <jats:italic>ESR1<\/jats:italic>\n                      -altered HR\u2009+\u2009\/HER2- BC, including\n                      <jats:italic>FGF3\/4\/19<\/jats:italic>\n                      and\n                      <jats:italic>CCND1<\/jats:italic>\n                      amplifications. No significant co-alterations were found in gynecologic cancer samples.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      <jats:italic>ESR1<\/jats:italic>\n                      alterations were most frequent in HR\u2009+\u2009\/HER2- BC samples and missense mutations were more frequent in metastatic samples, consistent with their role in ET resistance and disease progression.\n                      <jats:italic>ESR1<\/jats:italic>\n                      alterations co-occurred with therapeutically relevant alterations in other genes that may help inform clinical decision-making. Gynecologic tumors harbored\n                      <jats:italic>ESR1<\/jats:italic>\n                      alterations that have prognostic and potentially therapeutic relevance.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13058-025-02217-0","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T08:37:04Z","timestamp":1768811824000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Characterization of ESR1 alterations in patients with breast and gynecologic cancers"],"prefix":"10.1186","volume":"28","author":[{"given":"Gargi D.","family":"Basu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige E.","family":"Innis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela K.","family":"Deem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Starodynov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer S.","family":"Udhane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szabolcs","family":"Szelinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine R.","family":"LoBello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Baehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"De La O","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"O\u2019Shaughnessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"issue":"6","key":"2217_CR1","first-page":"524","volume":"72","author":"AN Giaquinto","year":"2022","unstructured":"Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72(6):524\u201341.","journal-title":"CA Cancer J Clin"},{"issue":"16","key":"2217_CR2","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","volume":"28","author":"ME Hammond","year":"2010","unstructured":"Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology\/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784\u201395.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2217_CR3","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288\u2013300.","journal-title":"JAMA"},{"issue":"32","key":"2217_CR4","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638\u201346.","journal-title":"J Clin Oncol"},{"issue":"10","key":"2217_CR5","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMoa2114663","volume":"386","author":"GN Hortobagyi","year":"2022","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386(10):942\u201350.","journal-title":"N Engl J Med"},{"issue":"18","key":"2217_CR6","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738\u201348.","journal-title":"N Engl J Med"},{"issue":"20","key":"2217_CR7","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925\u201336.","journal-title":"N Engl J Med"},{"issue":"19","key":"2217_CR8","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","volume":"377","author":"H Pan","year":"2017","unstructured":"Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836\u201346.","journal-title":"N Engl J Med"},{"issue":"7","key":"2217_CR9","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1080\/14737159.2019.1631799","volume":"19","author":"M Carausu","year":"2019","unstructured":"Carausu M, Bidard FC, Callens C, Melaabi S, Jeannot E, Pierga JY, et al. ESR1 mutations: a new biomarker in breast cancer. Expert Rev Mol Diagn. 2019;19(7):599\u2013611.","journal-title":"Expert Rev Mol Diagn"},{"issue":"3","key":"2217_CR10","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","volume":"34","author":"P Razavi","year":"2018","unstructured":"Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, et al. The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell. 2018;34(3):427\u201338.","journal-title":"Cancer Cell"},{"issue":"21","key":"2217_CR11","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.1002\/cncr.32345","volume":"125","author":"D Dustin","year":"2019","unstructured":"Dustin D, Gu G, Fuqua SAW. ESR1 mutations in breast cancer. Cancer. 2019;125(21):3714\u201328.","journal-title":"Cancer"},{"issue":"2","key":"2217_CR12","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10549-022-06740-y","volume":"196","author":"AL Heeke","year":"2022","unstructured":"Heeke AL, Elliott A, Feldman R, O\u2019Connor HF, Pohlmann PR, Lynce F, et al. Molecular characterization of ESR1 variants in breast cancer. Breast Cancer Res Treat. 2022;196(2):279\u201389.","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"2217_CR13","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1001\/jamaoncol.2016.1279","volume":"2","author":"S Chandarlapaty","year":"2016","unstructured":"Chandarlapaty S, Chen D, He W, Sung P, Samoila A, You D, et al. Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial. JAMA Oncol. 2016;2(10):1310\u20135.","journal-title":"JAMA Oncol"},{"issue":"313","key":"2217_CR14","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac7551","volume":"7","author":"G Schiavon","year":"2015","unstructured":"Schiavon G, Hrebien S, Garcia-Murillas I, Cutts RJ, Pearson A, Tarazona N, et al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci Transl Med. 2015;7(313):313ra182.","journal-title":"Sci Transl Med"},{"issue":"12","key":"2217_CR15","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/ng.2822","volume":"45","author":"W Toy","year":"2013","unstructured":"Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013;45(12):1439\u201345.","journal-title":"Nat Genet"},{"issue":"12","key":"2217_CR16","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1038\/ng.2823","volume":"45","author":"DR Robinson","year":"2013","unstructured":"Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446\u201351.","journal-title":"Nat Genet"},{"issue":"18","key":"2217_CR17","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1200\/JCO.23.00638","volume":"41","author":"HJ Burstein","year":"2023","unstructured":"Burstein HJ, DeMichele A, Somerfield MR, Henry NL. Testing for ESR1 mutations to guide therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline rapid recommendation update. J Clin Oncol. 2023;41(18):3423\u20135.","journal-title":"J Clin Oncol"},{"key":"2217_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22157812","author":"C Hernando","year":"2021","unstructured":"Hernando C, Ortega-Morillo B, Tapia M, Moragon S, Martinez MT, Eroles P, et al. Oral selective estrogen receptor degraders (SERDs) as a novel breast cancer therapy: present and future from a clinical perspective. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22157812.","journal-title":"Int J Mol Sci"},{"issue":"23","key":"2217_CR19","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1200\/JCO.2011.41.0076","volume":"30","author":"JM Albert","year":"2012","unstructured":"Albert JM, Liu DD, Shen Y, Pan IW, Shih YC, Hoffman KE, et al. Nomogram to predict the benefit of radiation for older patients with breast cancer treated with conservative surgery. J Clin Oncol. 2012;30(23):2837\u201343.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2217_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40487-017-0046-2","volume":"5","author":"MR Nathan","year":"2017","unstructured":"Nathan MR, Schmid P. A review of fulvestrant in breast cancer. Oncol Ther. 2017;5(1):17\u201329.","journal-title":"Oncol Ther"},{"issue":"6","key":"2217_CR21","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1080\/13543784.2021.1983542","volume":"31","author":"YC Chen","year":"2022","unstructured":"Chen YC, Yu J, Metcalfe C, De Bruyn T, Gelzleichter T, Malhi V, et al. Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer. Expert Opin Investig Drugs. 2022;31(6):515\u201329.","journal-title":"Expert Opin Investig Drugs"},{"issue":"28","key":"2217_CR22","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1200\/JCO.22.00338","volume":"40","author":"FC Bidard","year":"2022","unstructured":"Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial. J Clin Oncol. 2022;40(28):3246\u201356.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2217_CR23","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s10555-022-10066-y","volume":"41","author":"Y Wang","year":"2022","unstructured":"Wang Y, Tang SC. The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options. Cancer Metastasis Rev. 2022;41(4):975\u201390.","journal-title":"Cancer Metastasis Rev"},{"key":"2217_CR24","doi-asserted-by":"crossref","unstructured":"Bhave MA, Quintanilha JCF, Tukachinsky H, Li G, Scott T, Ross JS, Pasquina L, Huang RSP, McArthur H, Levy MA et al: Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice. Breast Cancer Res Treat 2024.","DOI":"10.1007\/s10549-024-07427-2"},{"issue":"20","key":"2217_CR25","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andr\u00e9","year":"2019","unstructured":"Andr\u00e9 F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380(20):1929\u201340.","journal-title":"N Engl J Med"},{"issue":"17","key":"2217_CR26","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","volume":"391","author":"NC Turner","year":"2024","unstructured":"Turner NC, Im SA, Saura C, Juric D, Loibl S, Kalinsky K, et al. Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer. N Engl J Med. 2024;391(17):1584\u201396.","journal-title":"N Engl J Med"},{"issue":"1","key":"2217_CR27","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ygyno.2019.04.010","volume":"154","author":"SL Gaillard","year":"2019","unstructured":"Gaillard SL, Andreano KJ, Gay LM, Steiner M, Jorgensen MS, Davidson BA, et al. Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies. Gynecol Oncol. 2019;154(1):199\u2013206.","journal-title":"Gynecol Oncol"},{"key":"2217_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153790","author":"D Stergiopoulou","year":"2022","unstructured":"Stergiopoulou D, Markou A, Giannopoulou L, Buderath P, Balgkouranidou I, Xenidis N, et al. Detection of ESR1 mutations in primary tumors and plasma cell-free DNA in high-grade serous ovarian carcinoma patients. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14153790.","journal-title":"Cancers (Basel)"},{"key":"2217_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000953","author":"N Dizman","year":"2020","unstructured":"Dizman N, Lyou Y, Salgia N, Bergerot PG, Hsu J, Enriquez D, et al. Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/jitc-2020-000953.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"2217_CR30","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.trecan.2019.03.005","volume":"5","author":"ES Knudsen","year":"2019","unstructured":"Knudsen ES, Pruitt SC, Hershberger PA, Witkiewicz AK, Goodrich DW. Cell cycle and beyond: exploiting new RB1 controlled mechanisms for cancer therapy. Trends Cancer. 2019;5(5):308\u201324.","journal-title":"Trends Cancer"},{"issue":"7","key":"2217_CR31","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1002\/cncr.31921","volume":"125","author":"SZ Millis","year":"2019","unstructured":"Millis SZ, Jardim DL, Albacker L, Ross JS, Miller VA, Ali SM, et al. Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities. Cancer. 2019;125(7):1185\u201399.","journal-title":"Cancer"},{"issue":"1","key":"2217_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00617-7","volume":"10","author":"N Chaudhary","year":"2024","unstructured":"Chaudhary N, Chibly AM, Collier A, Martinalbo J, Perez-Moreno P, Moore HM, et al. CDK4\/6i-treated HR+\/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape. NPJ Breast Cancer. 2024;10(1):15.","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"2217_CR33","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13058-025-02020-x","volume":"27","author":"K Venetis","year":"2025","unstructured":"Venetis K, Cursano G, Scafetta R, Giachetti P, Concardi A, De Camilli E, et al. ESR1 testing on FFPE samples from metastatic lesions in HR + \/HER2- breast cancer after progression on CDK4\/6 inhibitor therapy. Breast Cancer Res. 2025;27(1):79.","journal-title":"Breast Cancer Res"},{"issue":"16","key":"2217_CR34","doi-asserted-by":"publisher","first-page":"e13097","DOI":"10.1200\/JCO.2024.42.16_suppl.e13097","volume":"42","author":"N Dempsey","year":"2024","unstructured":"Dempsey N, Bhatt P, Lewis C, Tolman D, Chamorro Y, Rubens M, et al. Co-occurrence of ESR1 and PIK3CA mutations in HR+\/HER2- metastatic breast cancer: Incidence and outcomes with targeted therapy. J Clin Oncol. 2024;42(16):e13097\u2013e13097.","journal-title":"J Clin Oncol"},{"key":"2217_CR35","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241297101","volume":"16","author":"\u00dcM Tokat","year":"2024","unstructured":"Tokat \u00dcM, Bilgi\u00e7 \u015eN, Ayd\u0131n E, Adibi A, \u00d6zg\u00fc E, Tutar O, et al. Elacestrant plus alpelisib in an ESR1 and PIK3CA co-mutated and heavily pretreated metastatic breast cancer: the first case report for combination efficacy and safety. Ther Adv Med Oncol. 2024;16:17588359241297101.","journal-title":"Ther Adv Med Oncol"},{"issue":"2","key":"2217_CR36","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ccell.2017.07.005","volume":"32","author":"LR Yates","year":"2017","unstructured":"Yates LR, Knappskog S, Wedge D, Farmery JHR, Gonzalez S, Martincorena I, et al. Genomic evolution of breast cancer metastasis and relapse. Cancer Cell. 2017;32(2):169-184.e167.","journal-title":"Cancer Cell"},{"issue":"7538","key":"2217_CR37","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/nature13948","volume":"518","author":"D Juric","year":"2015","unstructured":"Juric D, Castel P, Griffith M, Griffith OL, Won HH, Ellis H, et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)K\u03b1 inhibitor. Nature. 2015;518(7538):240\u20134.","journal-title":"Nature"},{"issue":"21","key":"2217_CR38","doi-asserted-by":"publisher","first-page":"9233","DOI":"10.7314\/APJCP.2014.15.21.9233","volume":"15","author":"JL Ba","year":"2014","unstructured":"Ba JL, Liu CG, Jin F. Alterations in hormonal receptor expression and HER2 status between primary breast tumors and paired nodal metastases: discordance rates and prognosis. Asian Pac J Cancer Prev. 2014;15(21):9233\u20139.","journal-title":"Asian Pac J Cancer Prev"},{"key":"2217_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11579","volume":"7","author":"JM Spoerke","year":"2016","unstructured":"Spoerke JM, Gendreau S, Walter K, Qiu J, Wilson TR, Savage H, et al. Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. Nat Commun. 2016;7:11579.","journal-title":"Nat Commun"},{"key":"2217_CR40","doi-asserted-by":"publisher","first-page":"1372947","DOI":"10.3389\/fonc.2024.1372947","volume":"14","author":"T Reinert","year":"2024","unstructured":"Reinert T, do Rego FO, Silva MCE, Rodrigues AM, Koyama FC, Gon\u00e7alves AC, Pauletto MM, de Carvalho Oliveira LJ, de Resende CAA, Landeiro LCG, et al. The somatic mutation profile of estrogen receptor-positive HER2-negative metastatic breast cancer in Brazilian patients. Front Oncol. 2024;14:1372947.","journal-title":"Front Oncol"},{"issue":"7757","key":"2217_CR41","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41586-019-1056-z","volume":"569","author":"F Bertucci","year":"2019","unstructured":"Bertucci F, Ng CKY, Patsouris A, Droin N, Piscuoglio S, Carbuccia N, et al. Genomic characterization of metastatic breast cancers. Nature. 2019;569(7757):560\u20134.","journal-title":"Nature"},{"issue":"7","key":"2217_CR42","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1158\/1078-0432.CCR-13-2332","volume":"20","author":"R Jeselsohn","year":"2014","unstructured":"Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-Angulo AM, et al. Emergence of constitutively active estrogen receptor-\u03b1 mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res. 2014;20(7):1757\u201367.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2217_CR43","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1158\/2159-8290.CD-15-1523","volume":"7","author":"W Toy","year":"2017","unstructured":"Toy W, Weir H, Razavi P, Lawson M, Goeppert AU, Mazzola AM, et al. Activating ESR1 mutations differentially affect the efficacy of ER antagonists. Cancer Discov. 2017;7(3):277\u201387.","journal-title":"Cancer Discov"},{"issue":"1","key":"2217_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-018-0968-0","volume":"20","author":"V Allouchery","year":"2018","unstructured":"Allouchery V, Beaussire L, Perdrix A, Sefrioui D, Augusto L, Guillemet C, et al. Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients. Breast Cancer Res. 2018;20(1):40.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"2217_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2022.188830","volume":"1878","author":"A Grinshpun","year":"2023","unstructured":"Grinshpun A, Chen V, Sandusky ZM, Fanning SW, Jeselsohn R. ESR1 activating mutations: from structure to clinical application. Biochim Biophys Acta Rev Cancer. 2023;1878(1):188830.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"1","key":"2217_CR46","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12943-018-0808-y","volume":"17","author":"T Takeshita","year":"2018","unstructured":"Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Tomiguchi M, Sueta A, Murakami K, et al. Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer. Mol Cancer. 2018;17(1):67.","journal-title":"Mol Cancer"},{"issue":"2","key":"2217_CR47","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s10549-019-05512-5","volume":"180","author":"T Shibayama","year":"2020","unstructured":"Shibayama T, Low SK, Ono M, Kobayashi T, Kobayashi K, Fukada I, et al. Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer. Breast Cancer Res Treat. 2020;180(2):331\u201341.","journal-title":"Breast Cancer Res Treat"},{"key":"2217_CR48","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.2147\/CMAR.S249041","volume":"12","author":"H Liao","year":"2020","unstructured":"Liao H, Li H. Advances in the detection technologies and clinical applications of circulating tumor DNA in metastatic breast cancer. Cancer Manag Res. 2020;12:3547\u201360.","journal-title":"Cancer Manag Res"},{"issue":"5","key":"2217_CR49","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.tranon.2017.07.004","volume":"10","author":"T Takeshita","year":"2017","unstructured":"Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Tomiguchi M, Sueta A, Murakami K, et al. Comparison of ESR1 mutations in tumor tissue and matched plasma samples from metastatic breast cancer patients. Transl Oncol. 2017;10(5):766\u201371.","journal-title":"Transl Oncol"},{"key":"2217_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115739","volume":"228","author":"C Valenza","year":"2025","unstructured":"Valenza C, Curigliano G. Positioning oral selective estrogen receptor degraders in patients with metastatic breast cancer. Eur J Cancer. 2025;228:115739.","journal-title":"Eur J Cancer"},{"issue":"6","key":"2217_CR51","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1056\/NEJMoa2502929","volume":"393","author":"FC Bidard","year":"2025","unstructured":"Bidard FC, Mayer EL, Park YH, Janni W, Ma C, Cristofanilli M, et al. First-line camizestrant for emerging ESR1-mutated advanced breast cancer. N Engl J Med. 2025;393(6):569\u201380.","journal-title":"N Engl J Med"},{"issue":"3","key":"2217_CR52","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.cell.2022.01.003","volume":"185","author":"B Nguyen","year":"2022","unstructured":"Nguyen B, Fong C, Luthra A, Smith SA, DiNatale RG, Nandakumar S, et al. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell. 2022;185(3):563-575.e511.","journal-title":"Cell"},{"issue":"1","key":"2217_CR53","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.23199","volume":"63","author":"I Grote","year":"2024","unstructured":"Grote I, Poppe A, Lehmann U, Christgen M, Kreipe H, Bartels S. Frequency of genetic alterations differs in advanced breast cancer between metastatic sites. Genes Chromosomes Cancer. 2024;63(1):e23199.","journal-title":"Genes Chromosomes Cancer"},{"key":"2217_CR54","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ejca.2020.11.005","volume":"143","author":"L Gerratana","year":"2021","unstructured":"Gerratana L, Davis AA, Polano M, Zhang Q, Shah AN, Lin C, et al. Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools. Eur J Cancer. 2021;143:147\u201357.","journal-title":"Eur J Cancer"},{"issue":"10","key":"2217_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103731","volume":"9","author":"L Boscolo Bielo","year":"2024","unstructured":"Boscolo Bielo L, Guerini Rocco E, Trapani D, Zagami P, Taurelli Salimbeni B, Esposito A, et al. Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations. ESMO Open. 2024;9(10):103731.","journal-title":"ESMO Open"},{"issue":"2","key":"2217_CR56","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s10549-024-07255-4","volume":"205","author":"Y Wu","year":"2024","unstructured":"Wu Y, Li Z, Lee AV, Oesterreich S, Luo B. Liver tropism of ER mutant breast cancer is characterized by unique molecular changes and immune infiltration. Breast Cancer Res Treat. 2024;205(2):371\u201386.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"2217_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-018-0047-0","volume":"2","author":"W Chen","year":"2018","unstructured":"Chen W, Hoffmann AD, Liu H, Liu X. Organotropism: new insights into molecular mechanisms of breast cancer metastasis. NPJ Precis Oncol. 2018;2(1):4.","journal-title":"NPJ Precis Oncol"},{"issue":"2","key":"2217_CR58","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/PAP.0000000000000140","volume":"24","author":"S Wei","year":"2017","unstructured":"Wei S, Siegal GP. Metastatic organotropism: an intrinsic property of breast cancer molecular subtypes. Adv Anat Pathol. 2017;24(2):78\u201381.","journal-title":"Adv Anat Pathol"},{"key":"2217_CR59","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.12792","author":"SW Fanning","year":"2016","unstructured":"Fanning SW, Mayne CG, Dharmarajan V, Carlson KE, Martin TA, Novick SJ, et al. Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation. Elife. 2016. https:\/\/doi.org\/10.7554\/eLife.12792.","journal-title":"Elife"},{"issue":"4","key":"2217_CR60","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/nchembio.76","volume":"4","author":"KW Nettles","year":"2008","unstructured":"Nettles KW, Bruning JB, Gil G, Nowak J, Sharma SK, Hahm JB, et al. NFkappaB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses. Nat Chem Biol. 2008;4(4):241\u20137.","journal-title":"Nat Chem Biol"},{"key":"2217_CR61","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.72512","author":"DJ Hosfield","year":"2022","unstructured":"Hosfield DJ, Weber S, Li NS, Sauvage M, Joiner CF, Hancock GR, et al. Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in ESR1 mutant breast cancer cells. Elife. 2022. https:\/\/doi.org\/10.7554\/eLife.72512.","journal-title":"Elife"},{"issue":"2","key":"2217_CR62","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ccell.2018.01.004","volume":"33","author":"R Jeselsohn","year":"2018","unstructured":"Jeselsohn R, Bergholz JS, Pun M, Cornwell M, Liu W, Nardone A, et al. Allele-specific chromatin recruitment and therapeutic vulnerabilities of ESR1 activating mutations. Cancer Cell. 2018;33(2):173\u201386.","journal-title":"Cancer Cell"},{"issue":"2","key":"2217_CR63","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/jnci\/djk020","volume":"99","author":"M Dowsett","year":"2007","unstructured":"Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A\u2019Hern R, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 2007;99(2):167\u201370.","journal-title":"J Natl Cancer Inst"},{"key":"2217_CR64","doi-asserted-by":"publisher","DOI":"10.20517\/2394-4722.2019.12","author":"JT Lei","year":"2019","unstructured":"Lei JT, Gou X, Seker S, Ellis MJ. ESR1 alterations and metastasis in estrogen receptor positive breast cancer. J Cancer Metastasis Treat. 2019. https:\/\/doi.org\/10.20517\/2394-4722.2019.12.","journal-title":"J Cancer Metastasis Treat"},{"issue":"5","key":"2217_CR65","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/gcc.23029","volume":"61","author":"SK Loo","year":"2022","unstructured":"Loo SK, Yates ME, Yang S, Oesterreich S, Lee AV, Wang XS. Fusion-associated carcinomas of the breast: diagnostic, prognostic, and therapeutic significance. Genes Chromosomes Cancer. 2022;61(5):261\u201373.","journal-title":"Genes Chromosomes Cancer"},{"key":"2217_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5577","volume":"5","author":"J Veeraraghavan","year":"2014","unstructured":"Veeraraghavan J, Tan Y, Cao XX, Kim JA, Wang X, Chamness GC, et al. Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers. Nat Commun. 2014;5:4577.","journal-title":"Nat Commun"},{"issue":"7781","key":"2217_CR67","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41586-019-1689-y","volume":"575","author":"P Priestley","year":"2019","unstructured":"Priestley P, Baber J, Lolkema MP, Steeghs N, de Bruijn E, Shale C, et al. Pan-cancer whole-genome analyses of metastatic solid tumours. Nature. 2019;575(7781):210\u20136.","journal-title":"Nature"},{"issue":"4","key":"2217_CR68","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1093\/annonc\/mdy025","volume":"29","author":"RJ Hartmaier","year":"2018","unstructured":"Hartmaier RJ, Trabucco SE, Priedigkeit N, Chung JH, Parachoniak CA, Vanden Borre P, et al. Recurrent hyperactive ESR1 fusion proteins in endocrine therapy resistant breast cancer. Ann Oncol. 2018;29(4):872\u201380.","journal-title":"Ann Oncol"},{"key":"2217_CR69","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ebiom.2017.06.024","volume":"22","author":"P Jiang","year":"2017","unstructured":"Jiang P, Li Y, Poleshko A, Medvedeva V, Baulina N, Zhang Y, et al. The protein encoded by the CCDC170 breast cancer gene functions to organize the Golgi-microtubule network. EBioMedicine. 2017;22:28\u201343.","journal-title":"EBioMedicine"},{"key":"2217_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1155540","volume":"13","author":"Z Nagy","year":"2023","unstructured":"Nagy Z, Jeselsohn R. Corrigendum: ESR1 fusions and therapeutic resistance in metastatic breast cancer. Front Oncol. 2023;13:1155540.","journal-title":"Front Oncol"},{"issue":"1","key":"2217_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01325-3","volume":"22","author":"L Li","year":"2020","unstructured":"Li L, Lin L, Veeraraghavan J, Hu Y, Wang X, Lee S, et al. Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance. Breast Cancer Res. 2020;22(1):84.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"2217_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09265-1","volume":"22","author":"SR Vitale","year":"2022","unstructured":"Vitale SR, Ruigrok-Ritstier K, Timmermans AM, Foekens R, Trapman-Jansen AMAC, Beaufort CM, et al. The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer. BMC Cancer. 2022;22(1):165.","journal-title":"BMC Cancer"},{"issue":"33","key":"2217_CR73","doi-asserted-by":"publisher","first-page":"4581","DOI":"10.1038\/s41388-018-0284-2","volume":"37","author":"LA Gates","year":"2018","unstructured":"Gates LA, Gu G, Chen Y, Rohira AD, Lei JT, Hamilton RA, et al. Proteomic profiling identifies key coactivators utilized by mutant ER\u03b1 proteins as potential new therapeutic targets. Oncogene. 2018;37(33):4581\u201398.","journal-title":"Oncogene"},{"key":"2217_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/npjbcancer.2016.37","volume":"2","author":"K Adelson","year":"2016","unstructured":"Adelson K, Ramaswamy B, Sparano JA, Christos PJ, Wright JJ, Raptis G, et al. Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial. NPJ Breast Cancer. 2016;2:16037.","journal-title":"NPJ Breast Cancer"},{"issue":"2","key":"2217_CR75","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1093\/oncolo\/oyac248","volume":"28","author":"JO Brett","year":"2023","unstructured":"Brett JO, Ritterhouse LL, Newman ET, Irwin KE, Dawson M, Ryan LY, et al. Clinical implications and treatment strategies for ESR1 fusions in hormone receptor-positive metastatic breast cancer: a case series. Oncologist. 2023;28(2):172\u20139.","journal-title":"Oncologist"},{"issue":"5","key":"2217_CR76","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401\u20134.","journal-title":"Cancer Discov"},{"issue":"2","key":"2217_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188595","volume":"1876","author":"A Servetto","year":"2021","unstructured":"Servetto A, Formisano L, Arteaga CL. FGFR signaling and endocrine resistance in breast cancer: challenges for the clinical development of FGFR inhibitors. Biochim Biophys Acta Rev Cancer. 2021;1876(2):188595.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"31","key":"2217_CR78","doi-asserted-by":"publisher","first-page":"49091","DOI":"10.18632\/oncotarget.10077","volume":"7","author":"M Kaibori","year":"2016","unstructured":"Kaibori M, Sakai K, Ishizaki M, Matsushima H, De Velasco MA, Matsui K, et al. Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment. Oncotarget. 2016;7(31):49091\u20138.","journal-title":"Oncotarget"},{"issue":"4","key":"2217_CR79","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1002\/hep.25956","volume":"57","author":"T Arao","year":"2013","unstructured":"Arao T, Ueshima K, Matsumoto K, Nagai T, Kimura H, Hagiwara S, et al. FGF3\/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma. Hepatology. 2013;57(4):1407\u201315.","journal-title":"Hepatology"},{"issue":"2","key":"2217_CR80","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1200\/JOP.2016.011486","volume":"13","author":"DS Haslem","year":"2017","unstructured":"Haslem DS, Van Norman SB, Fulde G, Knighton AJ, Belnap T, Butler AM, et al. A retrospective analysis of precision medicine outcomes in patients with advanced cancer reveals improved progression-free survival without increased health care costs. J Oncol Pract. 2017;13(2):e108\u201319.","journal-title":"J Oncol Pract"},{"key":"2217_CR81","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1200\/PO.20.00445","volume":"5","author":"A Bardia","year":"2021","unstructured":"Bardia A, Su F, Solovieff N, Im SA, Sohn J, Lee KS, et al. Genomic profiling of premenopausal HR+ and HER2- metastatic breast cancer by circulating tumor DNA and association of genetic alterations with therapeutic response to endocrine therapy and ribociclib. JCO Precis Oncol. 2021;5:1408.","journal-title":"JCO Precis Oncol"},{"issue":"8","key":"2217_CR82","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/1078-0432.CCR-21-3276","volume":"28","author":"SM Tolaney","year":"2022","unstructured":"Tolaney SM, Toi M, Neven P, Sohn J, Grischke EM, Llombart-Cussac A, et al. Clinical significance of PIK3CA and ESR1 mutations in circulating tumor DNA: analysis from the MONARCH 2 study of abemaciclib plus fulvestrant. Clin Cancer Res. 2022;28(8):1500\u20136.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2217_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09068-2","volume":"10","author":"L Formisano","year":"2019","unstructured":"Formisano L, Lu Y, Servetto A, Hanker AB, Jansen VM, Bauer JA, et al. Aberrant FGFR signaling mediates resistance to CDK4\/6 inhibitors in ER+ breast cancer. Nat Commun. 2019;10(1):1373.","journal-title":"Nat Commun"},{"issue":"7","key":"2217_CR84","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.1158\/0008-5472.CAN-05-4363","volume":"66","author":"CJ Creighton","year":"2006","unstructured":"Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM, El-Ashry D. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res. 2006;66(7):3903\u201311.","journal-title":"Cancer Res"},{"issue":"2","key":"2217_CR85","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.ygyno.2016.03.006","volume":"141","author":"FJ Backes","year":"2016","unstructured":"Backes FJ, Walker CJ, Goodfellow PJ, Hade EM, Agarwal G, Mutch D, et al. Estrogen receptor-alpha as a predictive biomarker in endometrioid endometrial cancer. Gynecol Oncol. 2016;141(2):312\u20137.","journal-title":"Gynecol Oncol"},{"issue":"9","key":"2217_CR86","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1101\/gr.244780.118","volume":"29","author":"Z Blanchard","year":"2019","unstructured":"Blanchard Z, Vahrenkamp JM, Berrett KC, Arnesen S, Gertz J. Estrogen-independent molecular actions of mutant estrogen receptor 1 in endometrial cancer. Genome Res. 2019;29(9):1429\u201341.","journal-title":"Genome Res"},{"key":"2217_CR87","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00882","volume":"9","author":"PA Konstantinopoulos","year":"2025","unstructured":"Konstantinopoulos PA, Cai M, Lee EK, Krasner C, Campos SM, Liu JF, et al. Serial circulating tumor dna sequencing to monitor response and define acquired resistance to Letrozole\/Abemaciclib in endometrial cancer. JCO Precis Oncol. 2025;9:e2400882.","journal-title":"JCO Precis Oncol"},{"issue":"11","key":"2217_CR88","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.3390\/cancers17111806","volume":"17","author":"S Paratore","year":"2025","unstructured":"Paratore S, Russo A, Blanco G, Lanzafame K, Giurato E, Bartoloni G, et al. Clinical application of next-generation sequencing for molecular classification in the management of endometrial cancer: an observational cohort study. Cancers (Basel). 2025;17(11):1806.","journal-title":"Cancers (Basel)"},{"key":"2217_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2024.101348","volume":"52","author":"PA Konstantinopoulos","year":"2024","unstructured":"Konstantinopoulos PA, Xiong N, Krasner C, Liu JF, Sawyer H, Polak M, et al. Combined aromatase, CDK4\/6 and PI3K blockade using letrozole\/abemaciclib\/LY3023414 in endometrial cancer. Gynecol Oncol Rep. 2024;52:101348.","journal-title":"Gynecol Oncol Rep"},{"issue":"8","key":"2217_CR90","doi-asserted-by":"publisher","first-page":"559","DOI":"10.2217\/fon-2022-1196","volume":"19","author":"N Turner","year":"2023","unstructured":"Turner N, Huang-Bartlett C, Kalinsky K, Cristofanilli M, Bianchini G, Chia S, et al. Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. Future Oncol. 2023;19(8):559\u201373.","journal-title":"Future Oncol"},{"key":"2217_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102825","volume":"130","author":"M Gheysen","year":"2024","unstructured":"Gheysen M, Punie K, Wildiers H, Neven P. Oral SERDs changing the scenery in hormone receptor positive breast cancer, a comprehensive review. Cancer Treat Rev. 2024;130:102825.","journal-title":"Cancer Treat Rev"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-025-02217-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-02217-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-02217-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T16:02:32Z","timestamp":1770307352000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-025-02217-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":91,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2217"],"URL":"https:\/\/doi.org\/10.1186\/s13058-025-02217-0","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"20 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patient data was deidentified prior to inclusion. The study was conducted under approved WCG IRB #1188387.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GDB, PEI, AKD, AS, SSU, SS, MW, JRL, FLB, and JDLO are employees of Exact Sciences. JO\u2019S reports consulting fees and payment or honoraria for lectures, presentations, speaker\u2019s bureaus, manuscript writing or educational events from Agendia, Amgen Biotechnology, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Eisai, G1 Therapeutics, Genentech, Gilead Sciences, Eli Lilly, Merck, Novartis, Pfizer, Pierre Fabre Pharmaceuticals, Puma Biotechnology, Roche, Sanofi, Seagen, Mersana, Stemline-Menarini, Jazz, Summitt, BioNTech, Ellipses, TerSera, J&J, Duality, Natera, Guardant, Tempus, Exact Sciences, Hibercell and Aadi.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}